CGON
CGON
NASDAQ · Biotechnology

Cg Oncology Inc

$69.62
+0.44 (+0.64%)
As of May 9, 1:20 AM ET ·
Financial Highlights (FY 2026)
Revenue
4.39M
Net Income
-174,733,415
Gross Margin
-15.0%
Profit Margin
-3,985.0%
Rev Growth
+176.6%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -15.0% 55.1% 55.1%
Operating Margin -4,722.1% -9,060.5% -15.6% -13.7%
Profit Margin -3,985.0% -7,343.0% -17.7% -17.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 4.39M 3.43M 1.61B 1.48B
Gross Profit -659,085 888.76M 815.58M
Operating Income -207,209,519 -311,055,140 -251,110,084 -202,451,059
Net Income -174,733,415 -239,151,834 -285,460,132 -250,904,762
Gross Margin -15.0% 55.1% 55.1%
Operating Margin -4,722.1% -9,060.5% -15.6% -13.7%
Profit Margin -3,985.0% -7,343.0% -17.7% -17.0%
Rev Growth +176.6% -52.1% +15.2% +12.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 11.64M 0 1.65B 1.56B
Total Equity 2.91B 2.51B 2.29B
D/E Ratio 0.00 0.66 0.68
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -205,651,145 -328,687,347 -344,556,820 -320,224,465
Free Cash Flow -296,727,069 -277,168,820